NeuroDerm

NeuroDerm operates at the intersection of specialty pharmaceuticals, drug-device combinations, and digital health, with a concentrated focus on Parkinson’s disease rather than a broad commercial portfolio. Its primary differentiator is ND0612, which combines proprietary liquid levodopa/carbidopa formulations with continuous subcutaneous delivery intended to reduce fluctuations associated with intermittent oral dosing. This places the company in the competitive landscape for advanced Parkinson’s therapies alongside established approaches such as intestinal infusion systems, injectable rescue therapies, and device-enabled continuous delivery programs. NeuroDerm’s position is also shaped by ownership: since Mitsubishi Tanabe Pharma acquired it in 2017 for $1.1 billion, the company benefits from pharmaceutical-group resources but is less comparable to independently financed venture-stage biotechs. Its 81 granted patents, late-stage clinical focus, and regulatory progress for ND0612 provide stronger differentiation than its relatively narrow product breadth. The company’s historical $170.5 million in funding and public-market history reflect substantial capital intensity typical of CNS drug development.

NeuroDerm’s trajectory shows a progression from early-stage CNS biotechnology to a strategically acquired clinical-stage pharmaceutical business. The company was founded in 2003 and raised a $2.5 million Series A in 2007, followed by a $16 million Venture Round in 2014 led by The Elias Group. It went public on Nov 14, 2014, then raised $77 million and $75 million in post-IPO equity in 2015 and 2016, bringing recorded funding to $170.5 million. The major inflection point came on Jul 24, 2017, when Mitsubishi Tanabe Pharma announced a $1.1 billion cash acquisition; NeuroDerm was subsequently delisted on Oct 18, 2017. Since then, growth has been driven less by external fundraising and more by advancing ND0612 through clinical, regulatory, and evidence-generation milestones. Employee data places the organization in the 101–250 range, while six current leadership positions are listed. No hiring expansion or recent layoffs are reported.